Companies › Resverlogix
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Apabetalone (RVX000222) Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 2 | Post-Acute COVID-19 Syndrome | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06590324 | Apabetalone (RVX000222) | Phase 2 | Post-Acute COVID-19 Syndrome | Infectious disease | Dec 2025 |
Novartis Chia Tai Tianqing Pharmaceutical Group Bristol-Myers Squibb
Vasomune Therapeutics Altesa Biosciences Eagle Pharmaceuticals Code Pharma Peptilogics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.